Pure Global
NCT05743465

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Evaluate the Real-World Safety Outcomes and Clinical Efficacy of Ponatinib and Other Tyrosine Kinase Inhibitors Among Chronic Myeloid Leukemia Patients
Takeda·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Leukemia
Drug/Device/Intervention
No Intervention
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Takeda
Location
Cambridge, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 06, 2021
End date
Nov 30, 2022
Enrollment
1769 participants
Primary outcome

Number of Chronic Myeloid Leukemia (CML) Participants Categorized by Sociodemographic Variables at Diagnosis,Number of CML Participants With Baseline Clinical Characteristics of Disease Severity,Quan-Charlson Comorbidity Index Score,Number of CML Participants With Baseline Clinical Characteristics of Comorbidities,Number of CML Participants With Baseline Clinical Characteristics of Concomitant Medication,Number of Previous Treatments of Tyrosine Kinase Inhibitors (TKI) Drugs in Participants with CML,Duration Between Last TKI Run-out Date to the Index Date for Participants with CML,Number of Participants with Bone Marrow Stem Cell Transplant,Clinical Characteristics Assessed by Number of Participants With Major Adverse Cardiac Events (MACE), Arterial Occlusive Events (AOEs), and Venous Thrombotic Events (VTEs),Treatment Patterns Based on Duration of Index Treatment

Summary

The aims of this study are to learn out about treatment information (including amongst others
 treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib,
 imatinib, dasatinib and nilotinib using already available data. No new data will be collected
 from participants as part of this study and no study medicines will be provided in this
 study.

ICD-10 classifications
Leukaemia, unspecifiedMyeloid leukaemiaMyeloid leukaemia, unspecifiedOther myeloid leukaemiaMonocytic leukaemia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05743465
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05743465 through Pure Global AI's free database. This phase not specified trial is sponsored by Takeda and is currently Completed. The study focuses on Leukemia. Target enrollment is 1769 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.